Guideline for Diagnosis and Management of Vaginitis Presenting with Discharge and Mild Odor
Diagnostic Approach
- The three most common causes of vaginitis—bacterial vaginosis, trichomoniasis, and vulvovaginal candidiasis—should be evaluated with a proper vaginal examination and wet‑mount microscopy (CDC MMWR Recommendations) [1][2]3.
- Wet‑mount preparation: dilute a sample of vaginal discharge in 1–2 drops of 0.9 % saline on one slide and apply 10 % potassium hydroxide (KOH) on a second slide (CDC MMWR Recommendations) 1.
- An immediate amine ( “fishy”) odor after KOH application is indicative of bacterial vaginosis or trichomoniasis (CDC MMWR Recommendations) [1][2].
- Microscopic examination should assess for motile Trichomonas vaginalis trophozoites, clue cells (bacterial vaginosis), or yeast/pseudohyphae (candidiasis) (CDC MMWR Recommendations) 1.
Bacterial Vaginosis (BV)
- Diagnosis requires ≥ 3 of the 4 Amsel criteria: homogeneous white discharge, vaginal pH > 4.5, positive whiff test, and clue cells comprising > 20 % of epithelial cells (CDC MMWR Recommendations) [1][2]3.
- First‑line therapy: metronidazole 500 mg orally twice daily for 7 days (CDC MMWR Recommendations) [1][2]3.
- Alternative single‑dose regimen: metronidazole 2 g orally once (CDC MMWR Recommendations) [1][2].
- Patients should avoid alcohol during treatment and for 24 hours after completing therapy (CDC MMWR Recommendations) [1][2].
Trichomoniasis
- Typical presentation includes a diffuse, malodorous yellow‑green discharge (CDC MMWR Recommendations) [4][5].
- First‑line therapy: metronidazole 2 g orally as a single dose (CDC MMWR Recommendations) [4][5]6; an alternative is metronidazole 500 mg orally twice daily for 7 days (CDC MMWR Recommendations) [4][5]6.
- All sexual partners must be treated simultaneously (CDC MMWR Recommendations) [4][5]7.
- Patients should abstain from sexual activity until both partners have completed therapy and are asymptomatic (CDC MMWR Recommendations) [4][7].
Vulvovaginal Candidiasis
- Usually associated with a normal vaginal pH ≤ 4.5 (CDC MMWR Recommendations) [4][7]8.
- Clinical hallmark is pruritus that predominates over odor (CDC MMWR Recommendations) [4][8].
- Recommended treatment: intravaginal azole preparations (e.g., clotrimazole, miconazole) for 3–7 days (CDC MMWR Recommendations) [7][8]9.
Management Algorithm
Partner Management
- Partner treatment is not required for bacterial vaginosis or vulvovaginal candidiasis, but is mandatory for trichomoniasis (CDC MMWR Recommendations) [4][1]2.
Empiric Management of Bacterial Vaginosis (BV) When Molecular Testing Is Indeterminate
First‑Line Pharmacologic Therapy
- The CDC recommends metronidazole 500 mg orally twice daily for 7 days as the preferred treatment for symptomatic BV. 10
Alternative Regimens (when first‑line is unsuitable)
- A single oral dose of metronidazole 2 g can be used, but it achieves a lower cure rate (≈84 %) compared with the 7‑day regimen (≈95 %). 11
- Intravaginal clindamycin cream 2 % (5 g applicator) administered nightly for 7 days is an effective alternative. 11
- Intravaginal metronidazole gel 0.75 % (5 g applicator) applied twice daily for 5 days is another option. 11
Patient Counseling Recommendations
- Patients should avoid all alcohol during metronidazole therapy and for at least 24 hours after completion to prevent disulfiram‑like reactions. 11
Diagnostic Context Supporting Treatment
- In women presenting with malodorous vaginal discharge without predominant itching, the clinical picture argues against vulvovaginal candidiasis, reinforcing the BV diagnosis. 10
Partner Management
- The CDC states that treating male partners of women with BV is not indicated, as partner therapy does not reduce recurrence or improve outcomes. 11
Management of Asymptomatic Positive Molecular Tests
- Approximately 20 % of asymptomatic women may have a positive BV molecular panel; treatment is recommended only for those with symptoms. 11